The Manila Times10d
LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil Immunotherapies
LIfT's newly granted US patent (US 12,070,473 B2) secures robust protection for the treatment of cancer, including the use of ...
My doctor turned me away when I complained about a persistent cough at 16... weeks later I received the devastating cancer diagnosis that changed my life forever
Daisy first went to the GP in March 2023 where she was prescribe antibiotics for a suspected chest infection. She also found ...
Finanznachrichten10d
LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil Immunotherapies
LIfT's newly granted US patent (US 12,070,473 B2) secures robust protection for the treatment of cancer, including the use of granulocytes derived from haematopoietic stem cells (HSCs), induced ...
Operation beauty duty! Edwina Batholomew shares VERY revealing images of her glam squad at work on Sunrise set
Edwina Batholomew has taken viewers behind-the-scenes to reveal the secret behind the glamorous look she sports on Sunrise ...
The Scientist11d
Mapping the Shift from Healthy Stem Cells to Oral Cancer
Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...
Informationsdienst Wissenschaft3d
New junior research group investigates immune response to stress and its potential impact on cardiovascular health
Home > Press release: New junior research group investigates ...
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the ...
Yahoo Finance20d
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
“The study provides robust evidence for targeting residual disease in the bone and bone marrow, a common niche for chemoresistant cells in patients with primary refractory or relapsed disease.